MacroGenics to Participate in Upcoming Investor Conferences
31 Agosto 2023 - 5:30PM
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company
focused on developing, manufacturing and commercializing innovative
antibody-based therapeutics for the treatment of cancer, today
announced that the Company's management will participate in the
following upcoming investor conferences:
- Citi’s 18th Annual BioPharma Conference
(Boston). Scott Koenig, M.D., Ph.D., MacroGenics’
President and CEO, will participate in an ADC/Next Gen Panel
Discussion on Wednesday, September 6, 2023, at 10:30 am
ET. MacroGenics’ management will also participate in
one-on-one meetings.
- H.C. Wainwright’s 25th Annual Global Investment
Conference (New York). Scott Koenig, M.D., Ph.D., will
provide a corporate presentation on Monday, September 11, 2023, at
2:30 pm ET. MacroGenics’ management will also participate in
one-on-one meetings.
Webcasts of the above presentations may be accessed under
"Events & Presentations" in the Investor Relations section of
MacroGenics' website at http://ir.macrogenics.com/events.cfm.
The Company will maintain archived replays of these webcasts on its
website for 30 days.
About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused
on developing, manufacturing and commercializing innovative
monoclonal antibody-based therapeutics for the treatment of cancer.
The Company generates its pipeline of product candidates primarily
from its proprietary suite of next-generation antibody-based
technology platforms, which have applicability across broad
therapeutic domains. The combination of MacroGenics' technology
platforms and protein engineering expertise has allowed the Company
to generate promising product candidates and enter into several
strategic collaborations with global pharmaceutical and
biotechnology companies. For more information, please see the
Company's website at www.macrogenics.com. MacroGenics and the
MacroGenics logo are trademarks or registered trademarks of
MacroGenics, Inc.
###
CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024